Recent Insider Transactions • May 03
Independent Non-Executive Chairman recently bought CA$95k worth of stock On the 1st of May, J. Mills bought around 50k shares on-market at roughly CA$1.89 per share. This transaction increased J.'s direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. J. has been a buyer over the last 12 months, purchasing a net total of CA$166k worth in shares. Reported Earnings • May 01
First quarter 2026 earnings released: CA$0.04 loss per share (vs CA$0.057 loss in 1Q 2025) First quarter 2026 results: CA$0.04 loss per share (improved from CA$0.057 loss in 1Q 2025). Revenue: CA$195.9m (down 4.4% from 1Q 2025). Net loss: CA$9.91m (loss narrowed 33% from 1Q 2025). Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in Canada. 공시 • Apr 16
SNDL Inc. to Report Q1, 2026 Results on Apr 29, 2026 SNDL Inc. announced that they will report Q1, 2026 results Pre-Market on Apr 29, 2026 공시 • Mar 31
SNDL Inc. Announces Executive Changes for Cannabis Segment SNDL Inc. announced on March 30, 2026 that Tyler Robson, President of Cannabis, has left the Company in order to pursue other opportunities. Ryan Hellard, SNDL’s current Chief Strategy Officer, will assume the role of Interim President of Cannabis. The Company wishes Mr. Robson success in his future endeavours. New Risk • Mar 15
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 13% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 13% per year for the foreseeable future. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CA$21m net loss in 2 years). New Risk • Mar 13
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$16m Forecast net loss in 2 years: CA$21m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 13
Full year 2025 earnings released: CA$0.06 loss per share (vs CA$0.36 loss in FY 2024) Full year 2025 results: CA$0.06 loss per share (improved from CA$0.36 loss in FY 2024). Revenue: CA$946.4m (up 2.8% from FY 2024). Net loss: CA$15.8m (loss narrowed 83% from FY 2024). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. 공시 • Feb 20
SNDL Inc. to Report Q4, 2025 Results on Mar 12, 2026 SNDL Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 12, 2026 Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Independent Director James Cannell was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 공시 • Nov 22
SNDL Inc. (NasdaqCM:SNDL) announces an Equity Buyback for 24,500,000 shares, for CAD 100 million. SNDL Inc. (NasdaqCM:SNDL) announces a share repurchase program. Under the program, the company will repurchase up to 24,500,000 common shares, representing 10% of its issued share capital for CAD 100 million. The purpose of the program is opportunistically return value to shareholders. All shares purchased pursuant to the Share Repurchase Program will be returned to treasury for cancellation. The program is valid till November 20, 2026. New Risk • Nov 17
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$92m Forecast net loss in 1 year: CA$3.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Recent Insider Transactions • Nov 10
Independent Non-Executive Chairman recently bought CA$72k worth of stock On the 6th of November, J. Mills bought around 40k shares on-market at roughly CA$1.79 per share. This transaction increased J.'s direct individual holding by 40000x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was J.'s only on-market trade for the last 12 months. Reported Earnings • Nov 04
Third quarter 2025 earnings released: CA$0.05 loss per share (vs CA$0.073 loss in 3Q 2024) Third quarter 2025 results: CA$0.05 loss per share (improved from CA$0.073 loss in 3Q 2024). Revenue: CA$244.2m (up 3.1% from 3Q 2024). Net loss: CA$13.3m (loss narrowed 31% from 3Q 2024). Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. 공시 • Oct 16
SNDL Inc. to Report Q3, 2025 Results on Nov 04, 2025 SNDL Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Nov 04, 2025 Reported Earnings • Aug 01
Second quarter 2025 earnings released: EPS: CA$0.01 (vs CA$0.022 loss in 2Q 2024) Second quarter 2025 results: EPS: CA$0.01 (up from CA$0.022 loss in 2Q 2024). Revenue: CA$244.8m (up 7.3% from 2Q 2024). Net income: CA$2.89m (up CA$8.66m from 2Q 2024). Profit margin: 1.2% (up from net loss in 2Q 2024). Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in Canada. 공시 • Jul 11
SNDL Inc. to Report Q2, 2025 Results on Jul 31, 2025 SNDL Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 31, 2025 공시 • Jun 23
SNDL Inc., Annual General Meeting, Jul 29, 2025 SNDL Inc., Annual General Meeting, Jul 29, 2025. New Risk • May 14
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$107m Forecast net loss in 1 year: CA$9.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (CA$9.5m net loss next year). Reported Earnings • May 02
First quarter 2025 earnings released: CA$0.06 loss per share (vs CA$0.01 loss in 1Q 2024) First quarter 2025 results: CA$0.06 loss per share (further deteriorated from CA$0.01 loss in 1Q 2024). Revenue: CA$204.9m (up 3.6% from 1Q 2024). Net loss: CA$14.7m (loss widened 476% from 1Q 2024). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in Canada. 공시 • Apr 15
SNDL Inc. to Report Q1, 2025 Results on May 01, 2025 SNDL Inc. announced that they will report Q1, 2025 results Pre-Market on May 01, 2025 
